Etezad Razavi Mohammad, Sharifi Mohammad, Armanfar Fateme
Associate Professor of Ophthalmology, Eye Research Center of Mashhad University of Medical Sciences , Mashhad , Iran .
Strabismus. 2014 Dec;22(4):176-81. doi: 10.3109/09273972.2014.962750. Epub 2014 Oct 14.
Multiple surgical interventions are burden to patients with intermittent exotropia (IXT) due to a high recurrence rate. This study was designed to evaluate the efficacy of botulinum toxin injection in the treatment of intermittent exotropia (IXT).
A total of 21 patients with IXT, who had a far deviation of less than 40 prism diopters (PD), were enrolled. All cases were followed for at least 6 months with non-surgical management and had decremented fusional control (increasing 3 or more scores in Newcastle Control Score [NCS]). Botulinum toxin was injected (10 units Dysport) to both lateral rectus muscles. Fusional control, sensory and motor status were evaluated at 1 day, 1 week, and 1, 3, and 6 months after injection to compare with the pre-injection values.
Fusional control (based on NCS) showed a significant improvement during 6-month follow-up. Mean NCS was 4.4±0.8 SD before botulinum toxin injection and 1.4±0.4 SD after 6 months (p<0.001). Evaluation of sensorial status with Worth Four Dot Test (WFDT) also demonstrated an improvement of fusion (the percentage of patients demonstrating fusion on WFDT were 10.5% before injection and 61.5% after 6 months). The mean far and near deviations decreased during 6 months of follow-up examination. Satisfactory outcome (stable binocular alignment of the eyes to an orthophoria+/-10 PD in primary position) for far distance was achieved in 38.1% at 6 months. The percentage of satisfactory outcome at near was 86% at 6 months follow-up examination.
Botulinum toxin injection to lateral rectus muscles seems to be a promising procedure in the management of fusional control, far and near deviations in patients with intermittent exotropia in short time.
由于复发率高,多次手术干预给间歇性外斜视(IXT)患者带来负担。本研究旨在评估肉毒杆菌毒素注射治疗间歇性外斜视(IXT)的疗效。
共纳入21例远距离斜视度小于40棱镜度(PD)的间歇性外斜视患者。所有病例均采用非手术治疗至少随访6个月,且融合控制能力下降(纽卡斯尔控制评分[NCS]增加3分或更多)。向双侧外直肌注射肉毒杆菌毒素(10单位Dysport)。在注射后1天、1周、1个月、3个月和6个月评估融合控制、感觉和运动状态,并与注射前的值进行比较。
在6个月的随访期间,融合控制(基于NCS)有显著改善。注射肉毒杆菌毒素前平均NCS为4.4±0.8标准差,6个月后为1.4±0.4标准差(p<0.001)。用Worth四点试验(WFDT)评估感觉状态也显示融合能力有所改善(在WFDT上显示融合的患者百分比在注射前为10.5%,6个月后为61.5%)。在6个月的随访检查中,远近斜视度均下降。6个月时,38.1%的患者在远距离达到满意结果(双眼在第一眼位稳定对齐至正位±10 PD)。在6个月的随访检查中,近距离满意结果的百分比为86%。
向外侧直肌注射肉毒杆菌毒素似乎是一种在短期内管理间歇性外斜视患者融合控制、远近斜视度的有前景的方法。